Skip to main content
. 2022 Sep 13;13:982238. doi: 10.3389/fphar.2022.982238

FIGURE 3.

FIGURE 3

Targeting IL-23 in autoimmune diseases. IL-23 inhibitors have been shown to be effective. Ustekinumab is an inhibitor targeting IL-23p40, Guselkumab and Risankizumab are specific inhibitors targeting IL-23p19. They each block the IL-23 signaling pathway by binding to the p40 subunit and p19 subunit, thereby inhibiting the immune response of TH17.